سوق الخلايا الجذعية المحفزة متعددة القدرات في أمريكا الشمالية (iPSCs) – اتجاهات الصناعة والتوقعات حتى عام 2029

Request for TOC طلب جدول المحتويات Speak to Analyst تحدث إلى المحلل Buy Now اشتري الآن Inquire Before Buying استفسر قبل Free Sample Report تقرير عينة مجاني

سوق الخلايا الجذعية المحفزة متعددة القدرات في أمريكا الشمالية (iPSCs) – اتجاهات الصناعة والتوقعات حتى عام 2029

  • Pharmaceutical
  • Published Report
  • Dec 2021
  • North America
  • 350 الصفحات
  • عدد الجداول: 74
  • عدد الأرقام: 46

سوق الخلايا الجذعية المحفزة متعددة القدرات في أمريكا الشمالية (iPSCs)، حسب مصدر الخلية (خلايا الجلد وخلايا الدم)، النوع (IPSCs البشرية وIPSCs الفأرية)، المنتج (الأدوات والمواد الاستهلاكية والمجموعات والخدمات)، التطبيقات (البحث الأكاديمي، الطب التجديدي، العلاج الخلوي، فحص السموم، اكتشاف الأدوية وتطويرها، نمذجة الأمراض، بنوك الخلايا الجذعية، الطباعة الحيوية ثلاثية الأبعاد وغيرها)، المستخدم النهائي (شركات التكنولوجيا الحيوية والأدوية، مختبرات الأبحاث، مختبرات التشخيص وغيرها)، قناة التوزيع (العطاءات المباشرة ومبيعات التجزئة)، الدولة (الولايات المتحدة وكندا والمكسيك) - اتجاهات الصناعة والتوقعات حتى عام 2029.

سوق الخلايا الجذعية المحفزة متعددة القدرات في أمريكا الشمالية

تحليل السوق والرؤى: سوق الخلايا الجذعية المحفزة متعددة القدرات في أمريكا الشمالية (iPSCs)

من المتوقع أن يكتسب سوق الخلايا الجذعية متعددة القدرات المستحثة في أمريكا الشمالية (iPSCs) نموًا في السوق في الفترة المتوقعة من 2022 إلى 2029. تحلل Data Bridge Market Research أن السوق ينمو بمعدل نمو سنوي مركب بنسبة 9.8٪ في الفترة المتوقعة من 2022 إلى 2029 ومن المتوقع أن يصل إلى 1،014.30 مليون دولار أمريكي بحلول عام 2029. تعمل أنشطة البحث المتزايدة حول علاجات الخلايا الجذعية كمحرك لنمو سوق الخلايا الجذعية متعددة القدرات المستحثة (iPSCs).

الخلايا الجذعية متعددة القدرات المستحثة هي نوع من الخلايا المشتقة من الأنسجة الجسدية البالغة والتي أعيد برمجتها بمجموعة من الجينات والعوامل لاكتساب طبيعة متعددة القدرات. تتم إضافة جينات وعوامل معينة للحصول على خصائص محددة للخلايا الجذعية الجنينية. الخلايا متعددة القدرات المستحثة متطابقة تقريبًا مع الخلايا المانحة، فهي تساعد في نمذجة المرض. تُستخدم الفيروسات الرجعية عادةً كناقلات لإعادة برمجة الخلايا الجذعية متعددة القدرات المستحثة. التطبيقات الرئيسية للخلايا الجذعية متعددة القدرات المستحثة هي في نمذجة المرض واكتشاف الأدوية وتطويرها ودراسات السمية والعلاجات الجينية. تُستخدم على نطاق واسع في علاج أمراض القلب والأوعية الدموية ومرض السكري وأنواع مختلفة من السرطان. تُظهر الخلايا الجذعية متعددة القدرات المستحثة لدى البشر الخصائص ذات الصلة بالمرض لأنها تحمل النمط الجيني المحدد للمرض، وبالتالي تمكن من خيارات علاجية جديدة بطريقة خاصة بالمريض.

إن زيادة استخدام العلاج بالخلايا الجذعية، ونمو قطاع التكنولوجيا الحيوية مع تحسن الاستثمار وارتفاع معدل انتشار الأمراض المزمنة، كلها عوامل تعمل كمحرك لسوق الخلايا الجذعية المحفزة متعددة القدرات (iPSCs). ومن بين العوامل الأخرى التي من المتوقع أن تدفع نمو سوق الخلايا الجذعية المحفزة متعددة القدرات في أمريكا الشمالية، النطاق الواسع للتطبيقات السريرية للخلايا الجذعية المحفزة متعددة القدرات والتطورات التكنولوجية الناشئة للخلايا الجذعية المحفزة متعددة القدرات.

However, the factors such as the high cost associated with stem cell therapies, availability of alternatives for tumor treatment are hampering the growth of the North America induced pluripotent stem cells (iPSCs) market. On the other hand, the rising number of pipeline products, increased interest of personalized medicine and surge in healthcare expenditure act as an opportunity for the growth of the North America induced pluripotent stem cells (iPSCs) market. The stringent rules and regulations and Genomic instability of IPSC is the key market challenge faced in the North America induced pluripotent stem cells (iPSCs) market.

The induced pluripotent stem cells (iPSCs) market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the induced pluripotent stem cells (iPSCs) market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

سوق الخلايا الجذعية المحفزة متعددة القدرات في أمريكا الشمالية

Induced Pluripotent Stem Cells (iPSCs) Market Scope and Market Size

The induced pluripotent stem cells (iPSCs) market is segmented on basis of cell source, type, product, applications, end users and distribution channel The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

North America induced pluripotent stem cells (iPSCs) market is categorized into six notable segments based on the cell source, type, product, applications, end users and distribution channel.

  • On the basis of cell source, the North America induced pluripotent stem cells (iPSCs) market is segmented into skin cells and blood cells. In 2022, skin cells segment is expected to dominate the market due to wide availability of fibroblast and keratinocyte cells from skin surface for stem cell differentiation.
  • On the basis of type, the North America induced pluripotent stem cells (iPSCs) market is segmented into human IPSCs and mouse IPSCs. In 2022, human IPSCs segment is expected to dominate the market as the source of cells from patients with certain diseases can be specifically used for studying the stage of disorder.
  • On the basis of product, the North America induced pluripotent stem cells (iPSCs) market is segmented into instruments, consumables & kits and services. In 2022, consumables & kits segment is expected to dominate the market due to wide application of the stem cell kits in disease modelling and drug toxicity testing.
  • On the basis of application, the North America induced pluripotent stem cells (iPSCs) market is segmented into academic research, regenerative medicine, cellular therapy, toxicology screening, drug discovery and development, disease modelling, stem cell banking, 3D bioprinting and others. In 2022, drug discovery and development segment is expected to dominate the market as stem cells are used in innovative novel therapeutic invention for chronic diseases.
  • On the basis of end-users, the North America induced pluripotent stem cells (iPSCs) market is segmented into biotechnology & pharmaceutical companies, research laboratories, diagnostic laboratories and others. In 2022, biotechnology & pharmaceutical companies segment is expected to dominate the market due to high number of strategic initiatives taken by key players in the region.
  • On the basis of distribution channel, the North America induced pluripotent stem cells (iPSCs) market is segmented into direct tender and retail sales. In 2022, direct tender segment is expected to dominate the market due to high number of suppliers and transporting facilities managed by key manufacturers directly.

Induced Pluripotent Stem Cells (iPSCs) Market Country Level Analysis

The induced pluripotent stem cells (iPSCs) market is analyzed and market size information is provided by the country, cell source, type, product, applications, end users and distribution channel as referenced above.

The countries covered in the induced pluripotent stem cells (iPSCs) market report are the U.S., Canada and Mexico.

Biotechnology & Pharmaceutical companies segment.in U.S of North American region is expected to grow with the highest growth rate in the forecast period of 2022 to 2029 because of increasing usage of stem cell technology. The Biotechnology & Pharmaceutical companies segment in Canada is second dominating the market owing to increasing cases of chronic diseases and high adoption of stem cell sources for better therapies. Mexico is third in leading the growth of the market and Biotechnology & Pharmaceutical companies segment is dominating in this country due to increasing number of biotechnology centers and research activities.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Growing Strategic Activities by Major Market Players to Enhance the Awareness for Induced Pluripotent Stem Cells (iPSCs) Treatment, is Boosting the Market Growth of Induced Pluripotent Stem Cells (iPSCs) Market.

The induced pluripotent stem cells (iPSCs) market also provides you with detailed market analysis for every country growth in particular market. Additionally, it provides the detail information regarding the market players’ strategy and their geographical presence. The data is available for historic period 2011 to 2020.

Competitive Landscape and Induced Pluripotent Stem Cells (iPSCs) Market Share Analysis

Induced pluripotent stem cells (iPSCs) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to induced pluripotent stem cells (iPSCs) market.

The major companies which are dealing in the induced pluripotent stem cells (iPSCs) are Thermo Fisher Scientific Inc., FUJIFILM Corporation, LumaCyte,  Horizon Discovery Ltd., Hopstem Biotechnology LLC., Takara Bio Inc., Cell Applications, Inc., Citius Pharmaceuticals, Inc., Lonza., Evotec SE., Fate Therapeutics, Universal Cells Inc. (An Astellas Company), Axol Bioscience Ltd., R & D Systems, Inc., Charles River Laboratories International, Inc., Corning Incorporated, REPROCELL Inc., Applied StemCell., Merck KGaA, GeneCopoeia, Inc. and among other domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many contract and agreement are also initiated by the companies’ worldwide which are also accelerating the induced pluripotent stem cells (iPSCs) market.

For instance,

  • In February 2021, Thermo Fisher Scientific Inc. announced it has won six awards in the annual CMO Leadership Awards. The awards, presented by Life Science Leader and Outsourced Pharma, recognize top contract manufacturing partners as evaluated by biopharma and biotech companies. It is estimated that this recognition anticipated to strengthen company’s footprints in North America market and leading to upsurge company’s growth in the coming years.
  • In June 2020, the LumaCyte collaborated with Catalent who are the North America provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. This collaboration aided in expanding the company’s stem cell technology product Radiance and its application.

إن التعاون وإطلاق المنتج وتوسيع الأعمال والجوائز والتقدير والمشاريع المشتركة والاستراتيجيات الأخرى التي يتبعها اللاعب في السوق تعمل على تعزيز بصمة الشركة في سوق مضخات التسريب البيطرية مما يوفر أيضًا فائدة لنمو أرباح المنظمة.


SKU-

احصل على إمكانية الوصول عبر الإنترنت إلى التقرير الخاص بأول سحابة استخبارات سوقية في العالم

  • لوحة معلومات تحليل البيانات التفاعلية
  • لوحة معلومات تحليل الشركة للفرص ذات إمكانات النمو العالية
  • إمكانية وصول محلل الأبحاث للتخصيص والاستعلامات
  • تحليل المنافسين باستخدام لوحة معلومات تفاعلية
  • آخر الأخبار والتحديثات وتحليل الاتجاهات
  • استغل قوة تحليل المعايير لتتبع المنافسين بشكل شامل
طلب التجريبي

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 CELL SOURCE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET APPLICATION COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 NORTH AMERICA MEDICAL CARTS MARKET: REGULATIONS

5.1 REGULATION IN U.S.

5.2 REGULATION IN CANADA

5.3 REGULATION IN EUROPE

5.4 REGULATION IN INDIA

5.5 REGUALTION IN JAPAN

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 WIDE RANGE OF CLINICAL APPLICATION OF INDUCED PLURIPOTENT STEM CELLS

6.1.2 EMERGING TECHNOLOGICAL ADVANTAGES OF IPSCS

6.1.3 RISING PREVALENCE OF SEVERAL CHRONIC DISEASES

6.1.4 INCREASING ADOPTION OF STEM CELL THERAPY

6.1.5 GROWING BIOTECHNOLOGY SECTOR WITH BETTER INVESTMENT

6.2 RESTRAINT

6.2.1 HIGH COST ASSOCIATED WITH STEM CELL THERAPIES AND LARGE-SCALE APPLICATIONS OF IPSCS

6.2.2 AVAILABILITY OF ALTERNATIVES FOR TUMOR TREATMENT

6.2.3 ADVERSE EFFECTS OF STEM CELL TRANSPLANTS

6.3 OPPORTUNITIES

6.3.1 INCREASING NUMBER OF PIPELINE PRODUCTS

6.3.2 INCREASING INTEREST OF PERSONALIZED MEDICINE

6.3.3 SURGE IN HEALTHCARE EXPENDITURE

6.3.4 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS

6.4 CHALLENGES

6.4.1 GENOMIC INSTABILITY OF IPSCS IS THE KEY MARKET CHALLENGE

6.4.2 LACK OF SKILLED PROFESSIONALS

6.4.3 STRINGENT REGULATORY FRAMEWORK

7 IMPACT OF COVID-19 ON THE NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET

7.1 IMPACT ON PRICE

7.2 IMPACT ON DEMAND

7.3 IMPACT ON SUPPLY CHAIN

7.4 STRATEGIC DECISIONS BY MANUFACTURERS

7.5 CONCLUSION

8 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE

8.1 OVERVIEW

8.2 SKIN CELLS

8.2.1 FIBROBLAST

8.2.2 KERATINOCYTES

8.2.3 ADIPOSE DERIVED STEM CELLS

8.2.4 HEPATOCYTES

8.2.5 MELANOCYTES

8.2.6 NEURAL STEM CELLS

8.2.7 OTHERS

8.3 BLOOD CELLS

8.3.1 PERIPHERAL BLOOD

8.3.2 CORD BLOOD ENDOTHELIAL CELLS

8.3.3 CORD BLOOD STEM CELLS

8.3.4 OTHERS

9 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE

9.1 OVERVIEW

9.2 HUMAN IPSCS

9.3 MOUSE IPSCS

10 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT

10.1 OVERVIEW

10.2 CONSUMABLES & KITS

10.2.1 REPROGRAMMING KITS

10.2.2 MEDIA

10.2.3 TRANSFECTION KITS

10.2.4 CELL IDENTIFICATION KITS

10.2.5 ACCESSORIES

10.2.6 OTHERS

10.3 SERVICES

10.4 INSTRUMENTS

10.4.1 IMAGING SYSTEMS

10.4.2 ELECTROPORATION DEVICE

10.4.3 INCUBATORS

10.4.4 OTHERS

11 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION

11.1 OVERVIEW

11.2 DRUG DISCOVERY AND DEVELOPMENT

11.3 ACADEMIC RESEARCH

11.4 DISEASE MODELLING

11.5 CELLULAR THERAPY

11.6 REGENERATIVE MEDICINE

11.7 TOXICOLOGY SCREENING

11.8 STEM CELL BANKING

11.9 3D BIOPRINTING

11.1 OTHERS

12 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER

12.1 OVERVIEW

12.2 BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES

12.3 RESEARCH LABORATORIES

12.4 DIAGNOSTIC LABORATORIES

12.5 OTHERS

13 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL

13.1 OVERVIEW

13.2 DIRECT TENDER

13.3 RETAIL SALES

14 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION

14.1 NORTH AMERICA

14.1.1 U.S.

14.1.2 CANADA

14.1.3 MEXICO

15 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: COMPANY LANDSCAPE

15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

16 SWOT ANALYSIS

17 COMPANY PROFILE

17.1 FUJIFILM CORPORATION

17.1.1 COMPANY SNAPSHOT

17.1.2 REVENUE ANALYSIS

17.1.3 COMPANY SHARE ANALYSIS

17.1.4 PRODUCT PORTFOLIO

17.1.5 RECENT DEVELOPMENT

17.1.5.1 ACQUISITION

17.2 THERMO FISHER SCIENTIFIC INC.

17.2.1 COMPANY SNAPSHOT

17.2.2 REVENUE ANALYSIS

17.2.3 COMPANY SHARE ANALYSIS

17.2.4 PRODUCT PORTFOLIO

17.2.5 RECENT DEVELOPMENTS

17.2.5.1 EVENT

17.2.5.2 ACQUISITION

17.3 LONZA.

17.3.1 COMPANY SNAPSHOT

17.3.2 REVENUE ANALYSIS

17.3.3 COMPANY SHARE ANALYSIS

17.3.4 PRODUCT PORTFOLIO

17.3.5 RECENT DEVELOPMENTS

17.3.5.1 EXPANSION

17.4 MERCK KGAA

17.4.1 COMPANY SNAPSHOT

17.4.2 REVENUE ANALYSIS

17.4.3 COMPANY SHARE ANALYSIS

17.4.4 PRODUCT PORTFOLIO

17.4.5 RECENT DEVELOPMENT

17.4.5.1 AGREEMENT

17.5 EVOTEC SE.

17.5.1 COMPANY SNAPSHOT

17.5.2 REVENUE ANALYSIS

17.5.3 COMPANY SHARE ANALYSIS

17.5.4 PRODUCT PORTFOLIO

17.5.5 RECENT DEVELOPMENTS

17.5.5.1 AGREEMENT

17.5.5.2 COLLABORATION

17.6 APPLIED STEMCELL.

17.6.1 COMPANY SNAPSHOT

17.6.2 PRODUCT PORTFOLIO

17.6.3 RECENT DEVELOPMENTS

17.6.3.1 PRODUCT LAUNCH

17.7 AXOL BIOSCIENCE LTD.

17.7.1 COMPANY SNAPSHOT

17.7.2 PRODUCT PORTFOLIO

17.7.3 RECENT DEVELOPMENTS

17.7.3.1 MERGER

17.7.3.2 PRODUCT LAUNCH

17.8 CELL APPLICATIONS, INC.

17.8.1 COMPANY SNAPSHOT

17.8.2 PRODUCT PORTFOLIO

17.8.3 RECENT DEVELOPMENT

17.8.3.1 PARTNERSHIP

17.9 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

17.9.1 COMPANY SNAPSHOT

17.9.2 REVENUE ANALYSIS

17.9.3 PRODUCT PORTFOLIO

17.9.4 RECENT DEVELOPMENT

17.9.4.1 ACQUISITION

17.1 CITIUS PHARMACEUTICALS, INC.

17.10.1 COMPANY SNAPSHOT

17.10.2 PRODUCT PORTFOLIO

17.10.3 RECENT DEVELOPMENT

17.10.3.1 AGREEMENT

17.11 CORNING INCORPORATED

17.11.1 COMPANY SNAPSHOT

17.11.2 REVENUE ANALYSIS

17.11.3 PRODUCT PORTFOLIO

17.11.4 RECENT DEVELOPMENT

17.11.4.1 AGREEMENT

17.12 FATE THERAPEUTICS

17.12.1 COMPANY SNAPSHOT

17.12.2 PRODUCT PORTFOLIO

17.12.3 RECENT DEVELOPMENT

17.12.3.1 CLINICAL TRIAL

17.13 GENECOPOEIA, INC.

17.13.1 COMPANY SNAPSHOT

17.13.2 PRODUCT PORTFOLIO

17.13.3 RECENT DEVELOPMENT

17.14 HOPSTEM BIOTECHNOLOGY LLC.

17.14.1 COMPANY SNAPSHOT

17.14.2 PRODUCT PORTFOLIO

17.14.3 RECENT DEVELOPMENT

17.14.3.1 PARTNERSHIP

17.15 HORIZON DISCOVERY LTD.

17.15.1 COMPANY SNAPSHOT

17.15.2 PRODUCT PORTFOLIO

17.15.3 RECENT DEVELOPMENT

17.16 LUMACYTE

17.16.1 COMPANY SNAPSHOT

17.16.2 PRODUCT PORTFOLIO

17.16.3 RECENT DEVELOPMENT

17.16.3.1 COLLABORATION

17.17 R & D SYSTEMS, INC.

17.17.1 COMPANY SNAPSHOT

17.17.2 REVENUE ANALYSIS

17.17.3 PRODUCT PORTFOLIO

17.17.4 RECENT DEVELOPMENT

17.18 REPROCELL INC.

17.18.1 COMPANY SNAPSHOT

17.18.2 PRODUCT PORTFOLIO

17.18.3 RECENT DEVELOPMENTS

17.18.3.1 COLLABORATION

17.18.3.2 FACILITY EXPANSION

17.18.3.3 SERVICE LAUNCH

17.19 TAKARA BIO INC.

17.19.1 COMPANY SNAPSHOT

17.19.2 REVENUE ANALYSIS

17.19.3 PRODUCT PORTFOLIO

17.19.4 RECENT DEVELOPMENTS

17.19.4.1 NEW FACILITY LAUNCH

17.2 UNIVERSAL CELLS INC. (AN ASTELLAS COMPANY)

17.20.1 COMPANY SNAPSHOT

17.20.2 REVENUE ANALYSIS

17.20.3 PRODUCT PORTFOLIO

17.20.4 RECENT DEVELOPMENT

17.20.4.1 ACQUISITION

18 QUESTIONNAIRE

19 RELATED REPORTS

List of Table

TABLE 1 NEW CANCER CASES, AGES 85+, IN THE U.S.

TABLE 2 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)

TABLE 3 NORTH AMERICA SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 NORTH AMERICA SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)

TABLE 5 NORTH AMERICA BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 6 NORTH AMERICA BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)

TABLE 7 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 8 NORTH AMERICA HUMAN IPSCS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 9 NORTH AMERICA MOUSE IPSCS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 11 NORTH AMERICA CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 NORTH AMERICA CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 13 NORTH AMERICA SERVICES IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 14 NORTH AMERICA INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 15 NORTH AMERICA INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 16 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 17 NORTH AMERICA DRUG DISCOVERY AND DEVELOPMENT IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 NORTH AMERICA ACADEMIC RESEARCH IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 NORTH AMERICA DISEASE MODELLING IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 NORTH AMERICA CELLULAR THERAPY IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 21 NORTH AMERICA REGENERATIVE MEDICINE IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 NORTH AMERICA TOXICOLOGY SCREENING IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 NORTH AMERICA STEM CELL BANKING IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 NORTH AMERICA 3D BIOPRINTING IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 NORTH AMERICA OTHERS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 27 NORTH AMERICA BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 28 NORTH AMERICA RESEARCH LABORATORIES IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 NORTH AMERICA DIAGNOSTIC LABORATORIES IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 NORTH AMERICA OTHERS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 31 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 32 NORTH AMERICA DIRECT TENDER IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 33 NORTH AMERICA RETAIL SALES IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 34 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 35 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)

TABLE 36 NORTH AMERICA SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)

TABLE 37 NORTH AMERICA BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)

TABLE 38 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 39 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 40 NORTH AMERICA INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 41 NORTH AMERICA CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 42 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 43 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 44 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 45 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)

TABLE 46 U.S. SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)

TABLE 47 U.S. BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)

TABLE 48 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 49 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 50 U.S. INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 51 U.S. CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 52 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 53 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 54 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 55 CANADA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)

TABLE 56 CANADA SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)

TABLE 57 CANADA BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)

TABLE 58 CANADA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 59 CANADA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 60 CANADA INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 61 CANADA CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 62 CANADA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 63 CANADA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 64 CANADA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 65 MEXICO INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)

TABLE 66 MEXICO SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)

TABLE 67 MEXICO BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)

TABLE 68 MEXICO INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 69 MEXICO INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 70 MEXICO INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 71 MEXICO CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)

TABLE 72 MEXICO INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 73 MEXICO INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 74 MEXICO INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

List of Figure

FIGURE 1 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: DBMR MARKET POSITION GRID

FIGURE 8 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 9 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: SEGMENTATION

FIGURE 11 THE WIDE RANGE OF CLINICAL APPLICATION OF INDUCED PLURIPOTENT STEM CELLS (IPSC) ARE EXPECTED TO DRIVE THE NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 SKIN CELLS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET IN 2022 & 2029

FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET

FIGURE 15 PREVALENCE OF CHRONIC DISEASES

FIGURE 16 NUMBER OF PEOPLE WITH DIABETES (MILLION) AMONG AGES 20–79 YEARS

FIGURE 17 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY CELL SOURCE, 2021

FIGURE 18 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY CELL SOURCE, 2020-2029 (USD MILLION)

FIGURE 19 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY CELL SOURCE, CAGR (2022-2029)

FIGURE 20 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY CELL SOURCE, LIFELINE CURVE

FIGURE 21 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY TYPE, 2021

FIGURE 22 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY TYPE, 2020-2029 (USD MILLION)

FIGURE 23 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 24 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY TYPE, LIFELINE CURVE

FIGURE 25 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY PRODUCT, 2021

FIGURE 26 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY PRODUCT, 2020-2029 (USD MILLION)

FIGURE 27 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY PRODUCT, CAGR (2022-2029)

FIGURE 28 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY PRODUCT, LIFELINE CURVE

FIGURE 29 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY APPLICATION, 2021

FIGURE 30 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY APPLICATION, 2020-2029 (USD MILLION)

FIGURE 31 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY APPLICATION, CAGR (2022-2029)

FIGURE 32 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 33 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY END USER, 2021

FIGURE 34 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY END USER, 2020-2029 (USD MILLION)

FIGURE 35 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY END USER, CAGR (2022-2029)

FIGURE 36 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY END USER, LIFELINE CURVE

FIGURE 37 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 38 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

FIGURE 39 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 40 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 41 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: SNAPSHOT (2021)

FIGURE 42 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY COUNTRY (2021)

FIGURE 43 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY COUNTRY (2022 & 2029)

FIGURE 44 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY COUNTRY (2021 & 2029)

FIGURE 45 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY CELL SOURCE (2022-2029)

FIGURE 46 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: COMPANY SHARE 2021 (%)

View Detailed Information Right Arrow

منهجية البحث

يتم جمع البيانات وتحليل سنة الأساس باستخدام وحدات جمع البيانات ذات أحجام العينات الكبيرة. تتضمن المرحلة الحصول على معلومات السوق أو البيانات ذات الصلة من خلال مصادر واستراتيجيات مختلفة. تتضمن فحص وتخطيط جميع البيانات المكتسبة من الماضي مسبقًا. كما تتضمن فحص التناقضات في المعلومات التي شوهدت عبر مصادر المعلومات المختلفة. يتم تحليل بيانات السوق وتقديرها باستخدام نماذج إحصائية ومتماسكة للسوق. كما أن تحليل حصة السوق وتحليل الاتجاهات الرئيسية هي عوامل النجاح الرئيسية في تقرير السوق. لمعرفة المزيد، يرجى طلب مكالمة محلل أو إرسال استفسارك.

منهجية البحث الرئيسية التي يستخدمها فريق بحث DBMR هي التثليث البيانات والتي تتضمن استخراج البيانات وتحليل تأثير متغيرات البيانات على السوق والتحقق الأولي (من قبل خبراء الصناعة). تتضمن نماذج البيانات شبكة تحديد موقف البائعين، وتحليل خط زمني للسوق، ونظرة عامة على السوق ودليل، وشبكة تحديد موقف الشركة، وتحليل براءات الاختراع، وتحليل التسعير، وتحليل حصة الشركة في السوق، ومعايير القياس، وتحليل حصة البائعين على المستوى العالمي مقابل الإقليمي. لمعرفة المزيد عن منهجية البحث، أرسل استفسارًا للتحدث إلى خبراء الصناعة لدينا.

التخصيص متاح

تعد Data Bridge Market Research رائدة في مجال البحوث التكوينية المتقدمة. ونحن نفخر بخدمة عملائنا الحاليين والجدد بالبيانات والتحليلات التي تتطابق مع هدفهم. ويمكن تخصيص التقرير ليشمل تحليل اتجاه الأسعار للعلامات التجارية المستهدفة وفهم السوق في بلدان إضافية (اطلب قائمة البلدان)، وبيانات نتائج التجارب السريرية، ومراجعة الأدبيات، وتحليل السوق المجدد وقاعدة المنتج. ويمكن تحليل تحليل السوق للمنافسين المستهدفين من التحليل القائم على التكنولوجيا إلى استراتيجيات محفظة السوق. ويمكننا إضافة عدد كبير من المنافسين الذين تحتاج إلى بيانات عنهم بالتنسيق وأسلوب البيانات الذي تبحث عنه. ويمكن لفريق المحللين لدينا أيضًا تزويدك بالبيانات في ملفات Excel الخام أو جداول البيانات المحورية (كتاب الحقائق) أو مساعدتك في إنشاء عروض تقديمية من مجموعات البيانات المتوفرة في التقرير.

Frequently Asked Questions

The North America Induced Pluripotent Stem Cells (iPSCs) Market size will be worth USD 1,014.30 million by 2029.
The North America Induced Pluripotent Stem Cells (iPSCs) Market growth rate will be 9.8% by 2029.
The Increasing adoption of stem cell therapy, growing biotechnology sector with better investment and rising prevalence of chronic diseases are the growth drivers of the North America Induced Pluripotent Stem Cells (iPSCs) Market.
The cell source, type, product, applications, end users and distribution channel are the factors on which the North America Induced Pluripotent Stem Cells (iPSCs) Market research is based.
The major companies in the North America Induced Pluripotent Stem Cells (iPSCs) Market are Thermo Fisher Scientific Inc., FUJIFILM Corporation, LumaCyte, Horizon Discovery Ltd., Hopstem Biotechnology LLC., Takara Bio Inc., Cell Applications, Inc., Citius Pharmaceuticals, Inc., Lonza., Evotec SE., Fate Therapeutics, Universal Cells Inc. (An Astellas Company), Axol Bioscience Ltd., R & D Systems, Inc., Charles River Laboratories International, Inc., Corning Incorporated, REPROCELL Inc., Applied StemCell., Merck KGaA, GeneCopoeia, Inc.